Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial. - Wikidata - awgldk - TriplyDB

Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.

Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.

http://www.wikidata.org/entity/Q36932702

about

Role of mTOR Inhibitors in Kidney Disease Sunitinib in the treatment of metastatic renal cell carcinoma Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy Renal cell carcinoma.Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma.Metastatic non-clear cell renal cell carcinoma: an evidence based review of current treatment strategies Therapeutic challenges in advanced renal cell carcinoma Improving our understanding of papillary renal cell carcinoma with integrative genomic analysis.Insights into the Genetic Basis of the Renal Cell Carcinomas from The Cancer Genome Atlas.Molecular analysis of aggressive renal cell carcinoma with unclassified histology reveals distinct subsets.Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.Genomic differences between black and white patients implicate a distinct immune response to papillary renal cell carcinoma.Update on the treatment of metastatic clear cell and non-clear cell renal cell carcinoma.Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation.Therapeutic Strategies for Hereditary Kidney Cancer.Therapeutic approaches in clear cell and non-clear cell renal cell carcinoma.Sunitinib in kidney cancer: 10 years of experience and development.Recent Advances in the Medical Treatment of Recurrent or Metastatic Renal Cell Cancer.Renal cell carcinoma: molecular characterization and evolving treatment paradigms.Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update.Characterizing the outcomes of metastatic papillary renal cell carcinoma.Multimodal treatment of advanced renal cancer in 2017.Treatment of renal cell carcinoma: Current status and future directions.Management of Atypical Renal Cell Carcinomas.Efficacy of PI3K/AKT/mTOR pathway inhibitors for the treatment of advanced solid cancers: A literature-based meta-analysis of 46 randomised control trials.SEOM clinical guideline for treatment of kidney cancer (2017).Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma.Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.Effect of silencing TEM8 gene on proliferation, apoptosis, migration and invasion of XWLC‑05 lung cancer cells.The kidney cancer research priority-setting partnership: Identifying the top 10 research priorities as defined by patients, caregivers, and expert clinicians.Phase II Trial and Correlative Genomic Analysis of Everolimus Plus Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma.Sunitinib in the treatment of renal cell carcinoma: an update on recent evidence.The Role of Everolimus in Renal Cell Carcinoma.Non-Clear Cell Renal Cell Carcinoma: Current Management and Best Practice Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy Treatment outcomes of metastatic nonclear cell renal cell carcinoma: A single institution retrospective analysis

P2860

Q26747506-355F5AA7-B0D1-49EA-8C18-CC308FA4CDD7 Q28072057-7CB5B023-7ABE-4F0C-A499-25555AD0680E Q28079861-167993EB-8C8E-42ED-B3E9-C4108713A775 Q30235364-41A981F2-D58A-4E0A-BAF9-56A98A113A56 Q33798092-36D90901-C7AF-4CB0-BED4-C7462B49640B Q35315403-F0AC5460-7211-43C0-BFBB-750CD6B93B07 Q36573665-F89F6290-CC13-472A-8E65-FC4F9F63A6B9 Q36829230-EE6C046E-300B-4C7C-8FA4-9E0093B246A0 Q37114357-4B20E073-6011-477C-AD30-23C9A9AAB1A5 Q37330688-DBA4BE74-E573-47B8-A281-B0B2022EF5B6 Q37414808-D89D11F9-DC9F-47D1-973A-64158C230A02 Q37706326-816B456F-1068-4C49-BF99-AD8C3488A6B8 Q38367115-97979F54-0CC2-4F7E-BBF7-2DD80EEEB1CD Q38673512-41CB97E6-A6ED-42E8-AF41-F2E777790A1D Q38871343-834CB493-F393-4EFF-B455-A3141D371B83 Q38880667-E97D861D-727F-4375-9F02-AD4F09129E1B Q39038214-49647076-AF50-42D3-82A8-DC372B0D7E29 Q39044249-2C84DC9A-E4CB-4A80-86FF-CCFCDE72B89B Q39157961-DC400D12-676F-46C9-AFDF-9C71EB099606 Q41091919-A4EECBFF-6810-4897-9E29-75D2BBB374DD Q41491779-EDBCA9AD-B624-4C72-9A4C-4BD673E7BE4E Q41531703-D36BD67B-056D-4DC6-AFB9-2792DAB5F0A4 Q42172414-198E0898-EEBF-4514-ACAD-85279012E9D7 Q47550490-7E29ECA2-704E-4848-A934-0EAC2C584FF8 Q47726014-AB961A2D-B127-4930-8606-0420C735E139 Q47947817-08A8CE37-E0DC-4787-AA90-54B41158244A Q48097821-9D9B29F1-7ABB-48F3-B56A-C3944D53BE83 Q48310227-45DF4ABE-D8BD-4797-91F9-1B0B98BBD7CC Q49186124-220FA41A-CD63-4859-B5C5-E0BF5DE4AA00 Q49573718-2E54B9C1-65FE-4AEF-986D-50B7E413BBA2 Q50111461-E492112D-BE71-4581-8527-B30F83B5504C Q50141378-A885450D-0FD0-47E4-A775-E80F4C65E0C9 Q50299194-1D65B0B5-60B8-4240-BCB5-C5692DA42643 Q52319542-4C1D6606-BAF5-423B-A74F-27FDB1CBF37F Q52979097-BE3844DF-480F-408A-B8C4-6C41AE20C78A Q58585079-3C5F3D7C-1CD1-4486-A768-A15F1ED680C5 Q58709993-7751F2E6-C549-466C-AE59-81A1FBFA89E7 Q59138470-EDE92191-5492-4B33-BC25-2713C9080086

P2860

Everolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.

http://www.wikidata.org/entity/Q36932702

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Everolimus Versus Sunitinib Pr ...... zed Multicenter Phase 2 Trial.

@en

type

label

Everolimus Versus Sunitinib Pr ...... zed Multicenter Phase 2 Trial.

@en

prefLabel

Everolimus Versus Sunitinib Pr ...... zed Multicenter Phase 2 Trial.

@en

P1433

Q36932702-D1E81441-9AE0-49DA-BDCB-D632C8D6B775

P1476

Q36932702-768BBCE1-40AE-46F4-97F3-8AF83855F86A

P2093

Q36932702-0E91B1FF-ED56-4C51-BA1B-474815CDAF04

Q36932702-262C6F30-FEDF-4DE0-81C8-5B5AC0B95329

Q36932702-2D49CA09-F0E6-469E-9B47-0CD8539371BD

Q36932702-4365BC12-2FC6-4E8C-BC21-D84394D3616B

Q36932702-5EA7AF8A-42F8-4F2A-8D88-0C5BF3BDB649

Q36932702-748B08B6-78C1-4A4C-BDEA-A09B188A17B9

Q36932702-76A9234A-3D9D-4DC4-B658-9726CD0C081B

Q36932702-9D46101B-2091-46EF-B56E-FDE68E5BAEFA

Q36932702-A7A67B55-AD38-44D6-B3E0-5EB1D97D31EA

Q36932702-B6859C62-3F4B-4D96-885B-983E7BCF213C

P2860

Q36932702-070006F3-D958-44D6-9361-480D4FDE6D7A

Q36932702-0C613A69-B841-4CDA-9963-A4478A212B1F

Q36932702-0CBD3FFA-2718-480A-9634-22F997CE1F55

Q36932702-1EC206CD-9AD2-45B4-9BD1-43D5163A0245

Q36932702-22051D5D-88AD-422E-81F9-D90B20CD49D2

Q36932702-23D150DC-6EF5-4205-AB52-1A32DB9CB340

Q36932702-3FF448A7-4A8E-4196-9E68-E97F24E55C60

Q36932702-487CF99E-E55F-49C7-A823-C5D355C895A5

Q36932702-4FA05EF9-2C6E-4AE0-9C7D-DA79E6470079

Q36932702-50383CFC-0F0B-45B5-B2A2-1E41434A5F71

P304

Q36932702-8F874180-9DBE-4C14-AE7B-355165F3FA42

P31

Q36932702-ED63C020-D640-4DB6-A964-8205F9E9A562

P356

Q36932702-865640B2-E9E4-4E61-AEB4-A68635F14AF6

P407

Q36932702-06124996-6B22-43F7-AFCF-B0167846D11E

P433

Q36932702-342D4A0A-0F18-4812-A393-9D979734345B

P478

Q36932702-A9193E48-E0A4-4EDB-8B1A-D8726C1A4894

P50

Q36932702-7A869038-EDD9-44ED-8614-BED458DB6FC7

P577

Q36932702-FEA7BCA7-C9B7-4E3A-BA08-956C3FD9A66D

P698

Q36932702-B3A24DAD-DAF8-4872-860A-EBA2AE13634E

P921

Q36932702-24CC7C8B-5085-4B57-8F76-B6946382966C

Q36932702-55080CF6-7C96-47B4-98E2-29F77EDF1E94

P932

Q36932702-E898B0FB-54C3-4C44-AFEC-F7165C4A8521

P356

J.EURURO.2015.10.049

P1433

European Urology

P1476

Everolimus Versus Sunitinib Pr ...... zed Multicenter Phase 2 Trial.

@en

P2093

Chaan S Ng

http://www.w3.org/2001/XMLSchema#string

Christopher G Wood

http://www.w3.org/2001/XMLSchema#string

David F McDermott

http://www.w3.org/2001/XMLSchema#string

Emre Altinmakas

http://www.w3.org/2001/XMLSchema#string

Eric Jonasch

http://www.w3.org/2001/XMLSchema#string

Jose A Karam

http://www.w3.org/2001/XMLSchema#string

Kanishka Sircar

http://www.w3.org/2001/XMLSchema#string

Laurence Albiges

http://www.w3.org/2001/XMLSchema#string

Nizar M Tannir

http://www.w3.org/2001/XMLSchema#string

Pheroze Tamboli

http://www.w3.org/2001/XMLSchema#string

P2860

Targeted therapies and the treatment of non-clear cell renal cell carcinoma

Response and acquired resistance to everolimus in anaplastic thyroid cancer

The somatic genomic landscape of chromophobe renal cell carcinoma

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial.

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.

Treatment outcome with mTOR inhibitors for metastatic renal cell carcinoma with nonclear and sarcomatoid histologies.

Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma

Sarcomatoid renal cell carcinoma: a comprehensive review of the biology and current treatment strategies.

P304

866-874

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURURO.2015.10.049

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

69

http://www.w3.org/2001/XMLSchema#string

P50

Laurence Albiges

P577

2015-11-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26626617

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

multicenter trial

P932

4879109

http://www.w3.org/2001/XMLSchema#string